Better treatments are needed for patients with diffuse large B-cell lymphoma (DLBCL) at high risk of failing standard therapy. Avoiding apoptosis is a hallmark of cancer, and in DLBCL the ...

If you or a loved one has diffuse large B-cell lymphoma (DLBCL) that is no longer responding to treatment or came back after treatment, chimeric antigen receptor (CAR) T-cell therapy may be an option.

Roche’s CD20xCD3 bispecific antibody Columvi has improved survival when used as a second-line therapy for diffuse large B-cell lymphoma (DLBCL) in a phase 3 trial, setting up regulatory filings ...

A regimen based on Roche's CD20xCD3 bispecific antibody Columvi has been approved in the EU as a second-line therapy for diffuse large B-cell lymphoma (DLBCL), the first in the class that can be ...

You've learned that you have diffuse large B-cell lymphoma (DLBCL). What happens now? A cancer diagnosis can feel overwhelming. You might not know what to do first. Start by having a conversation ...

Low immunoglobulin levels affect nearly 1 in 4 newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) and significantly increase infection risk during treatment. Patients with low ...

CEO Mallik emphasized the potential expansion of ZYNLONTA into earlier lines of diffuse large B-cell lymphoma (DLBCL) therapy through LOTIS-5 and LOTIS-7 studies. He stated that the LOTIS-5 ...